SCHEMBL15034892

SCHEMBL15034892

Cc1scnc1-c1cc2cnc(Nc3ccc(OC4CCNC4)cc3)nc2n(Cc2cnsc2C2CCNC2)c1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 6/20 0.35
FGFR4 P22455 5/20 0.35
KDR P35968 1/20 0.35
RIPK2 O43353 7/20 0.35
NOD2 Q9HC29 7/20 0.35
ACVR1 Q04771 6/20 0.35
PKN1 Q16512 2/20 0.34
PAK4 O96013 1/20 0.34
CDK4 P11802 4/20 0.34
CCNA2 P20248 4/20 0.34
FGFR2 P21802 4/20 0.34
FGFR3 P22607 4/20 0.34
CCND1 P24385 4/20 0.34
CDK2 P24941 4/20 0.34
JAK2 O60674 1/20 0.33
BRD4 O60885 1/20 0.33
JAK1 P23458 1/20 0.33
BRD2 P25440 1/20 0.33
JAK3 P52333 1/20 0.33
BRD3 Q15059 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034785 0.81 PAK1 (0.36) FGFR1FGFR4KDRRIPK2NOD2
SCHEMBL15035012 0.80 FGFR1 (0.34) FGFR1FGFR4KDRRIPK2NOD2
SCHEMBL15035788 0.79 RIPK2 (0.37) FGFR1FGFR4KDRRIPK2NOD2
SCHEMBL15035742 0.78 RIPK2 (0.37) FGFR1RIPK2NOD2ACVR1PKN1
SCHEMBL15035649 0.78 PRKCZ (0.33) RIPK2NOD2ACVR1PKN1PAK4
SCHEMBL15035037 0.77 PAK4 (0.38) FGFR1FGFR4KDRPKN1PAK4
SCHEMBL15034821 0.76 PAK4 (0.39) FGFR1FGFR4PKN1PAK4CDK4
SCHEMBL15034842 0.76 MAPK8 (0.38) FGFR1FGFR4RIPK2NOD2ACVR1
SCHEMBL15036172 0.76 CDK4 (0.37) FGFR1FGFR4CDK4CCNA2FGFR2
SCHEMBL15237005 0.76 JAK2 (0.36) FGFR1FGFR4KDRPKN1PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-05 US disclosed
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-05 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK3, PAK5 FGFR1 2874/4885FGFR4 2801/4885KDR 2034/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 FGFR1 1919/4885FGFR4 1949/4885KDR 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.